Background: Even though malaria incidence is decreasing worldwide, travel-related cases reported in Europe have remained stable in recent years. In Italy, incidence had increased in the 1990s, reaching a peak in 1999; a slow decline was then reported over the subsequent decade. To our knowledge, few published data are available on imported malaria in Italy since 2010. In this article we aimed to analyse trends in imported malaria in the teaching hospital of Brescia, northern Italy, over the last 18 years. Methods: All malaria cases diagnosed from 1999 to 2016 in Spedali Civili Hospital, Brescia, were retrospectively identified. Demographic, clinical and travel-related data were described. Results: A total of 1200 cases of imported malaria were diagnosed in Brescia during the study period. Among them, 225 were children. A trend of increasing paediatric cases was identified over the study period, while cases in adults were stable. Most cases were diagnosed between August and October. Patients were most likely exposed in sub-Saharan Africa (87.2%). The main reported travel reason was travelling to visit friends and relatives (66.0%). A significantly higher risk of severe malaria was observed in non-immune patients and children visiting friend and relatives (P < 0.001 and P = 0.006, respectively). Conclusions: Our study reveals a relatively stable incidence in imported malaria cases with a peak during the summertime. A large and increasing paediatric burden of disease was identified. Imported malaria requires attention since in Italy a potential reappearance of autochthonous Plasmodium vivax malaria transmission cannot be excluded. Preventive action and physician awareness should be especially directed to children visiting friends and relatives in endemic countries and to non-immune patients since they both represent high-risk groups for severe malaria.
malaria cases reported in Europe, Plasmodium falciparum is the predominant species, mainly detected in people visiting friends and relatives (VFR) in sub-Saharan Africa. Migrants reaching Europe for the first time represent a heterogeneous risk group depending on the country of origin and migration route. In recent years, Italy has faced a significant wave of migration from sub-Saharan Africa through the Mediterranean. According to the International Organization for Migration, 153 842 and 181 436 people arrived in Italy via the sea in 2015 and 2016, respectively, mainly coming from Nigeria, Eritrea, Guinea, Ivory Coast, Gambia, Senegal, Mali and Sudan. 11 Although malaria is typically unusual among newly arrived migrants, the possibility of relapsing forms caused by Plasmodium vivax or Plasmodium ovale should be considered as suggested in recent literature. 12, 13 Following France and UK, Italy is among the countries of the EU with the highest number of malaria cases. 2, 14 During the 1990s a rising trend in imported malaria was reported by the Italian National Health Institute, both due to migration and imported infections among Italian soldiers returning from United Nations missions in Somalia and Mozambique. 15 Since 1995 most cases were diagnosed among foreign-born people, with a slow decreasing incidence reported over much of the decade since 2000. 16 The aim of this paper is to describe the more recent epidemiological and clinical features of imported malaria cases diagnosed in the tertiary care teaching Hospital of Brescia, northern Italy.
Methods
We conducted a retrospective cohort study with systematic inclusion of all travellers with malaria hospitalized from 1 January 1999 to 31 December 2016 in Spedali Civili teaching Hospital, Brescia, Italy. The diagnosis was based on microscopic examination of Giemsa-stained thick and thin blood smears and/or antigen detection test and/or PCR. PCR has been available in our laboratory since 2011. Demographic, clinical and travel-related data were retrieved from a dedicated database and analysed. The reason for travel was classified according to GeoSentinel categories 17 as follows: VFR, immigration, missionary/volunteers/researcher/aid work, tourism and business. Patients aged <16 years were classified as children. Both adults and children were classified into one of two groups: (i) non-immune for travellers born in non-endemic areas and (ii) semi-immune for patients born in malaria-endemic areas including children who had come to Italy for the first time for immigration purposes. Severe malaria was defined according to 2010 WHO criteria. 18 A descriptive analysis was performed in order to assess gender distribution, age, reason for travel, area of exposure, Plasmodium species, time to treatment after symptom onset and chemoprophylaxis. Qualitative variables were expressed as relative and absolute frequencies, and quantitative data were expressed as median or mean values. 25th and 75th percentiles, and 95% confidence intervals (CI95) were calculated. Variation over time was estimated using a negative binomial regression model where number of cases was the dependent variable (outcome) and age (childhood vs adulthood), year of malaria occurrence and their interaction were independent variables. Statistical analysis were performed using StataTM version 14 software.
The study was conducted under the provisions of the Declaration of Helsinki, and in accordance with the International Conference on Harmonization Consolidated Guideline on Good Clinical Practice. Since this study was retrospective and nonpharmacological, a written informed consent was not provided. In Italy, ethical review board (ERB) authorization for these studies is not required (see Italian Guidelines for classification and conduction of observational studies, established by the Italian Drug Agency, 'Agenzia Italiana del Farmaco-AIFA' on 20 March 2008). However, the study was notified to the Provincial ERB, Province of Brescia.
Results

Patients
From 1999 to 2016, 1200 malaria cases were diagnosed in our centre; 975 (81.2%) in adults and 225 (18.8%) in children. All cases were determined to be imported malaria. However, for a Pakistani child, a genetic investigation is underway to discriminate between relapse and 'baggage' malaria. The main features of the study population are summarized in Table 1 . The mean age was 32.0 years (range: 0-80 years), 862 (71.8%) were males. Of the 1200 patients with malaria, 281 were born in malaria nonendemic areas, of whom 259 (92.2%) were born in Italy. Of these, 114 were children born in Italy to migrants parents, 97 of whom (85.1%) were originally from sub-Saharan Africa. Of the remaining patients with malaria, 919 were born in malariaendemic areas, including 3 (0.3%) from Latin America and Afghanistan, 830 from sub-Saharan Africa (90.3%), and 86 from the Indian subcontinent (9.4%), among whom 68 (79.1%) were from Pakistan.
Area of acquisition
A total of 1047 (87.2%) patients were exposed in sub-Saharan Africa, of whom 712 (68.0%) were settled migrants VFR in their home country. The most common African destinations were in West African Countries, especially Senegal (233/1047; 22.2%), Burkina Faso (194/104; 18.5%) and Nigeria (180/ 1047; 17.2%). Another 104 (8.7%) patients had destinations in the Indian subcontinent, including Pakistan (82), India (21) and Sri Lanka (1). Another 13 had destinations in other malaria-endemic areas, and in 36 cases the travel destination was unknown. Newly arrived migrants represented 11.8% of total cases (142/1200), most of them coming from West Africa (103/116, 88.8%). Since 2010, when the significant wave of migration through the Mediterranean started, 9.8% (49/501) of all malaria cases were diagnosed in newly arrived migrants. The majority of them arrived in Italy in 2010 and 2011 (14/49 and 13/49, respectively); in the following years the number of malaria cases diagnosed in people travelling for immigration purposes decreased. The median times between arrival or return from the malaria-endemic area and admission for P. falciparum and P. vivax malaria were 10 days (interquartile range 10 days) and 41 days (interquartile range: 182 days), respectively. Time-to-admission data were available for 716 of 990 patients with P. falciparum malaria and for 88 of 141 patients with P. vivax malaria.
Chemoprophylaxis
Among the 930 patients not travelling for immigration purposes and arriving from sub-Saharan Africa, where use of chemoprophylaxis is typically recommended, data on chemoprophylaxis were available for 644 (69.2%). Among these, the majority (635/644; 98.6%) did not take or were not compliant with chemoprophylaxis. Nine patients (1.4%) reported taking adequate chemoprophylaxis; among them, three were diagnosed with P.ovale malaria and six with P. falciparum malaria.
Plasmodium species
Plasmodium falciparum was diagnosed in 990 (82.5%) patients, 955 of them (96.5%) had travelled to sub-Saharan Africa, 8 (0.8%) to the Indian subcontinent and 1 (0.2%) to Southeast Asia, while for 26 (2.5%), their destinations were unknown. In contrast, 141 (11.7%) patients were diagnosed with P. vivax malaria. Of these, 94 (66.7%) had visited the Indian subcontinent, 29 (20.6%) sub-Saharan Africa, 5 (3.5%) Latin America, 6 (4.3%) Southeast Asia and 1 (0.7%) Afghanistan, while for 6 (4.2%) destinations were unknown. In other cases the following Plasmodium species were identified: 46 (3.8%) P. ovale, mainly from West Africa (35/46, 76.1%) and 21 (1.7%) P. malariae. Two mixed infections (one P. falciparum plus P. malariae and one P. falciparum plus P. vivax) were identified ( Figure 1 ).
Severe malaria
A total of 80 (6.7%) cases of malaria were classified as severe according to WHO criteria 2010; complication was specified in 76 cases. In 30 patients (39.4%) the diagnosis of severe malaria was based only on hyperparasitemia, whereas in 46 (60.6%) other complications occurred: seven central nervous system involvement, nine severe aneamia, seven hyperbilirubinemia, four acute respiratory distress syndrome (ARDS), six acute renal failure, five multiorgan failures and eight defined by multiple criteria. All severe cases except one ARDS caused by P. vivax, were due to P. falciparum. Two patients died (2.5% of severe cases and 0.2% of total Among adults with severe malaria, 38.3% were born in non-endemic countries. The proportion of severe malaria cases was significantly higher in nonimmune travellers, both in adults (odds ratio = 2.95; CI95: 1.61-5.40, P < 0.001) and children (odds ratio = 3.07; CI95: 1.30-7.25, P = 0.006), and in travellers VFR (odds ratio = 0.61; CI95: 0.36-1.02, P < 0.04) ( Table 2 ). In multivariate analysis, the same three variables were selected and travellers VFR did not show a statistically significant association with severe malaria ( 
Time trends
The number of cases of malaria diagnosed annually remained relatively stable from 1999 to 2016 among adults, while the number of cases among children demonstrated an increasing trend (P < 0.001); moreover, most cases were registered from August to October, peaking in September (P < 0.05 respect to April) as shown in Figure 2 .
Discussion
Over the 18-year period from 1999 to 2016 the number of malaria cases diagnosed annually at our centre has remained relatively stable in adults, while the number of cases among children demonstrated an increasing trend. Compared with malaria cases reported by the National Health Institute between 2000 and 2008, 16 the cases diagnosed in our centre represent~10% of all Italian cases in the same period. A fifth of patients are children VFR in endemic countries, half of them were born in Italy. As described in literature and highlighted in our study, patients admitted for malaria from non-endemic areas, especially children, have increased odds of being diagnosed with severe malaria, suggesting they should be a priority target for preventive interventions. 20 Primary prevention should be more strongly encouraged and barriers to receipt of safe and well-tolerated chemoprohylaxis and adherence with dosing should be explored. Poor compliance is known to be a common problem. Because travellers may be persuaded to suspend chemoprophylaxis by peer pressure, underestimation of mosquito presence and adverse reactions, clinicians should be prepared to address these barriers. Of available prophylactic drugs, mefloquine is very poorly tolerated, associated with a high risk of serious neuropsychiatric reactions, and is the subject of boxed warnings throughout Europe. 21 Similarly, doxycycline is often poorly tolerated, being associated with photosensitivity and gastrointestinal reactions. The best tolerated medication, atovaquone-proguanil, appears to be the most popular medication with travellers. However, it can be quite expensive and this could be the main barrier in some categories of travellers, especially VFR, often travelling with their children and spending long periods in malaria-endemic areas.
Only two fatal cases were identified in our study, both occuring before artesunate introduction in 2009; this low mortality is in line with European recent literature and it might reflect the high standard of intensive care along with an increased use of intravenous artesunate in the area. As reported in the literature, quinine is still widely used in Europe; this is mostly due to intravenous artesunate lacking European marketing authorization, although limited quantities are available through other mechanisms, and consequently the rate of patients receiving intravenous artesunate almost doubled in recent years. 22 In our centre P. vivax malaria is mainly diagnosed in Pakistani patients who account for 56.0% of all cases. A significant rise in imported cases from Pakistan's Punjab region was previously reported in recent years, mostly attributable to an increase of both Pakistani immigrants and malaria incidence in their region of origin. The phenomenon was interpreted as a consequence of multiple factors as climate change, recent flooding in the area, poor vector control and inadequate health care. 23 Although some
European countries reported an increase in number of P. vivax malaria cases due to recently arrived refugees from East Africa, in our centre we did not observe an analogous phenomenon, probably reflecting differences in migrant populations hosted in these areas. In our study, migrants reaching Italy for the first time were mostly coming from West African countries. Although the flow of migrants reaching Europe through the Mediterranean has increased in recent years, we did not observe a rise in the number of malaria cases in this group. This is likely due to the fact that our area is not the first place of arrival in Italy, or it may possibly be associated with a decrease in malaria incidence in West Africa. According to WHO, from 2010 to 2015 the incidence rate of malaria is estimated to have decreased by 21% in the WHO African Region. 24 Over the 18-year period of our study, seasonal trends in diagnosis are apparent, with most cases diagnosed from August to October, peaking in September, mainly related to the end of Italian summer holidays and the rainy season in malariaendemic countries in West Africa. This might have significant implications because the high number of imported cases and the documented presence of suitable Anopheline atroparvus vectors in our area during summer months might allow sporadic autochthonous transmission of P. vivax malaria.
As described in previous studies on migrant populations, the failure to perceive malaria as a personal risk or poor knowledge of the existence of protective measures lead to a low adoption of prophylaxis. 25, 26 Primary prevention should be more strongly encouraged, especially in most vulnerable people, as children and non-immune travellers exposing to P. falciparum; they represent almost a third of all cases in the study area and have a significantly higher risk of complications. We are aware that our study has a number of limitations. The classification of patients into non-immune and semi-immune may potentially overestimate the number of semi-immune patients, especially for children who lived in endemic area for <5 years, which is usually considered the age of semi-immune status acquisition. 27 Since the age of first arrival in Italy was mostly unknown, we classified children only on the basis of their country of birth. Nevertheless, children aged <5 years have already been included in semi-immune group in other studies on imported malaria. 28, 29 One study reported that immigrant children, including subjects younger than 5 years old, had a lower risk of severe malaria compared to children VFR born in non-endemic area, due to their semi-immune status. 30 Another limitation to be emphasized is that the semi-immune status of people born and raised in malariaendemic areas could be lost after a variable period of residence in a non-endemic area. However, it has been reported in literature that partial immunity could persist in immigrants even after many years. 31 Migrants recently arrived from malaria-endemic areas are a group for whom malaria is usually mild or asymptomatic due to partial immunity; however pregnant women and children have a higher risk of complications. Moreover, a good travel history should be collected in mobile populations, as highlighted by the case of P. vivax malaria reported in a child who reached Sweden through the Balkan route from Syria, which was considered malaria-free during peacetime. 32 The WHO's 'Global Technical Strategy for Malaria 2016-2030' calls for a continuous effort to continue reducing malaria incidence and mortality by 90% in high-burden countries. 33 Removing barriers to accessing health services, including safe and well-tolerated chemoprophylaxis for the prevention of malaria, and raising awareness of the risk of imported malaria among physicians to aid in the rapid detection and treatment of cases, are factors of pivotal importance for the prevention of secondary cases and disease outbreaks.
Conclusions
This is the largest analysis to date describing characteristics of travellers with malaria in Italy. Despite global improvements in malaria control, we do not observe a decline in the number of imported malaria cases. Recently arrived migrants do not represent a high-risk group for malaria; although the flow of migrants reaching Italy from sub-Saharan Africa has increased in recent years, the number of malaria cases in this group has not increased, likely reflecting decreasing incidence in the countries of origin. Malaria continues to pose a health risk to travellers. Nonimmune patients and people VFR, especially children, have a higher risk of severe malaria. Primary prevention should be promoted increasing risk awareness and improving affordability of welltolerated drugs. Surveillance of travel-related malaria infections is essential to travellers' health, as well as elimination efforts.
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